MISSD Board member, Kim Witzack, discusses the recent FDA approval of esketamine, a nasal spray to be marketed as an antidepressant. Witzack serves as a consumer representative on the FDA Advisory Committee. The FDA reviewed only one positive clinical trial before approving the drug.

See: https://www.madinamerica.com/2019/02/nasal-spray-for-depression/